

# Mitochondrial Abnormalities in Alzheimer's Disease

Keisuke Hirai,<sup>1,4</sup> Gjurmakch Aliev,<sup>2</sup> Akihiko Nunomura,<sup>1,5</sup> Hisashi Fujioka,<sup>1</sup> Robert L. Russell,<sup>1</sup> Craig S. Atwood,<sup>1</sup> Anne B. Johnson,<sup>6</sup> Yvonne Kress,<sup>6</sup> Harry V. Vinters,<sup>7</sup> Massimo Tabaton,<sup>8</sup> Shun Shimohama,<sup>9</sup> Adam D. Cash,<sup>1</sup> Sandra L. Siedlak,<sup>1</sup> Peggy L. R. Harris,<sup>1</sup> Paul K. Jones,<sup>3</sup> Robert B. Petersen,<sup>1</sup> George Perry,<sup>1</sup> and Mark A. Smith<sup>1</sup>

<sup>1</sup>Institute of Pathology, <sup>2</sup>Department of Neurology, and <sup>3</sup>Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, Ohio 44106, <sup>4</sup>Pharmaceutical Research Laboratories I, Pharmaceutical Research Division, Takeda Chemical Industries Ltd., Osaka, 532-8686 Japan, <sup>5</sup>Department of Psychiatry and Neurology, Asahikawa Medical College, Asahikawa, 078-8510 Japan, <sup>6</sup>Department of Pathology, Albert Einstein College of Medicine, Bronx, New York 10461, <sup>7</sup>Department of Pathology and Laboratory Medicine, University of California, Los Angeles, California 90024, <sup>8</sup>Department of Neuroscience, University of Genova, 16132 Genova, Italy, and <sup>9</sup>Department of Neurology, Kyoto University, Kyoto, 606-8507 Japan

The finding that oxidative damage, including that to nucleic acids, in Alzheimer's disease is primarily limited to the cytoplasm of susceptible neuronal populations suggests that mitochondrial abnormalities might be part of the spectrum of chronic oxidative stress of Alzheimer's disease. In this study, we used *in situ* hybridization to mitochondrial DNA (mtDNA), immunocytochemistry of cytochrome oxidase, and morphometry of electron micrographs of biopsy specimens to determine whether there are mitochondrial abnormalities in Alzheimer's disease and their relationship to oxidative damage marked by 8-hydroxyguanosine and nitrotyrosine. We found that the same neurons showing increased oxidative damage in Alzheimer's

disease have a striking and significant increase in mtDNA and cytochrome oxidase. Surprisingly, much of the mtDNA and cytochrome oxidase is found in the neuronal cytoplasm and in the case of mtDNA, the vacuoles associated with lipofuscin. Morphometric analysis showed that mitochondria are significantly reduced in Alzheimer's disease. The relationship shown here between the site and extent of mitochondrial abnormalities and oxidative damage suggests an intimate and early association between these features in Alzheimer's disease.

*Key words:* Alzheimer's disease; free radicals; metabolism; mitochondria; neurodegeneration; oxidative stress

The pathological presentation of Alzheimer's disease (AD) involves selective pyramidal neuronal death and an accumulation of intraneuronal and extracellular fibrils, neurofibrillary tangles (NFT), and senile plaques, respectively (Katzman, 1986; Smith, 1998). In a series of studies, we and others have shown that oxidative stress is involved not only in damage to the proteins of NFT and senile plaques but also involves extensive damage to the cytoplasm of neuronal populations vulnerable to death during AD (Montine et al., 1996; Smith et al., 1996, 1997; Sayre et al., 1997). What is particularly striking regarding neuronal damage is that those neurons displaying oxidative damage show no overt signs of visible degeneration (Sayre et al., 1997; Smith et al., 1997), leading us to consider whether more subtle cytological abnormalities might be associated with oxidative damage.

We undertook this study to determine whether mitochondria could be involved in this process because they can be both targets of oxidative damage and sources of reactive oxygen. Dysfunction of mitochondrial electron transport proteins has been associated with the pathophysiology of AD (Blass and Gibson, 1991), as well as in Parkinson's disease (Parker et al., 1989). Those studies that

analyzed mitochondrial function at the cellular level, through cytochrome oxidase activity measurements, have consistently shown activity deficits consistent with mitochondrial compromise (Wong-Riley et al., 1997). Furthermore, cytoplasmic hybrid cells in which mitochondria from sporadic cases of AD were fused with other cells also indicate a defect in mitochondria function in AD (Ghosh et al., 1999; Khan et al., 2000; Trimmer et al., 2000). However, these studies implicating mitochondrial abnormalities in AD were not focused on specific neuronal cytological abnormalities in mitochondria in vulnerable neurons and their relationship to oxidative damage.

In this study, we use cytological *in situ* hybridization, immunocytochemistry, and morphometry to determine whether mitochondrial abnormalities are associated with vulnerable neurons in AD. Our findings show major abnormalities in mitochondrial dynamics restricted to vulnerable neurons, suggesting an intimate relationship between mitochondria and oxidative damage in AD.

## MATERIALS AND METHODS

### Tissue

Brain tissue was obtained at autopsy from cases with a diagnosis of AD (Khachaturian, 1985; Mirra et al., 1991) as well as control cases with no clinical or pathological history of neurological disease. Hippocampal tissue, including the adjacent temporal cortex, cerebellum, and frontal cortex from 27 cases of AD (ages 57–93 years; postmortem intervals, 2–20.5 hr; average, 6.4 hr), 12 old control cases (ages 54–85 years; postmortem intervals, 3–34 hr; average, 13.8 hr), and eight young control cases (ages 3–49 years; postmortem intervals, 3–23 hr; average, 12.4 hr), was either fixed in methacarn (methanol–chloroform–acetic acid, 60:30:

Received Oct. 13, 2000; revised Feb. 14, 2001; accepted Feb. 16, 2001.


This work was supported by National Institutes of Health Grants AG09287, AG14249, P50 AG16570, and NS38648, the American Health Assistance Foundation and the United Mitochondrial Disease Foundation.

K.H. and G.A. contributed equally to this study.

Correspondence should be addressed to Dr. Mark A. Smith, Institute of Pathology, Case Western Reserve University, 2085 Adelbert Road, Cleveland, OH 44106. E-mail: mas21@po.cwru.edu.

Copyright © 2001 Society for Neuroscience 0270-6474/01/213017-07\$15.00/0

10) or 2% paraformaldehyde–0.5% glutaraldehyde at 4°C for 16 hr for light or electron microscopic examination, respectively. For light microscopy, after fixation, tissue was dehydrated through graded ethanol followed by xylene and embedded in paraffin. Sections, 6- $\mu$ m-thick, were cut and mounted on silane (Sigma, St. Louis, MO)-coated standard glass microscope slides for *in situ* hybridization and immunocytochemistry. For electron microscopy, tissue was sectioned at 60  $\mu$ m using a Vibratome and immunodecorated with colloidal gold.



**Figure 1.** Pyramidal neurons of the hippocampus, cells highly vulnerable to death in AD, show increased mtDNA in all cases of AD (*A*, mtDNA $\Delta$ 5kb, chimeric probe; *C*, wild-type mtDNA) compared with controls (*B*, mtDNA $\Delta$ 5kb, chimeric probe; *D*, wild-type mtDNA). *E*, Quantitative densitometric analysis of the level of mtDNA shows the increases are severalfold and significant ( $p = 0.0034$ ; Student's *t* test) for AD compared with old or young controls  $\pm$  SEMs. Scale bar, 10  $\mu$ m.


### Biopsy

Tissue was taken for diagnostic procedures from the frontal or temporal cortices of eight patients (age 53–84), most of which had been included in other clinicopathological studies (Stewart et al., 1992; Praprotnik et al., 1996a,b) and with a definite history (duration 3–11 years) and clinical presentation of dementia and fulfilling the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association working group criteria for probable AD (McKhann et al., 1984). Corresponding tissue from five patients (ages 62–80) suffering from various conditions such as hydrocephalus or brain tumor were also examined and used as controls. Tissue was fixed in 1.5% glutaraldehyde in cacodylate buffer and post-fixed in 1% osmium tetroxide for 1 hr immediately after removal from the brain. After dehydration in graded ethanol and propylene oxide, the tissue was embedded in Epon 812, sectioned at silver interference color, electron-contrasted with uranyl acetate and lead citrate, and grids were viewed at 80 kV using a JEOL 100CX electron microscope.


### In situ hybridization

**Light microscopy.** *In situ* hybridization was performed according to the method of Nakamura et al. (1996) with some modifications. Probes used for *in situ* analysis of mitochondrial DNA (mtDNA) were wild-type and with the common 5 kb deletion (mtDNA $\Delta$ 5kb). Four oligonucleotide probes, three of 45 bp and one of 29 bp in length, were constructed for the present study. The probes, designated “chimera”, include the mtDNA region from nucleotide coordinate 8454 to 8482 of ATPase subunit 8 and from 13460 to 13475 of NADH-coenzyme Q oxidoreductase subunit 5 and the “chimera short” included the mtDNA region from 8454 to 8482. The probes designated as “wild 1” and “wild 2” contain a fragment that spans nucleotides from 10897 to 10941 and from 10981 to 11025 of ND4L. The GC content of each 45 bp probe is 51.1%, and the sequences of the probes lack long palindromic sequences. All probes to mtDNA were synthesized, labeled by digoxigenin, and purified by Operon Technologies (Alameda, CA): *Alu*I and 2 repeat sequences were found exclusively in nuclear DNA (Research Genetics, Huntsville, AL).

After deparaffinization, the sections were rinsed with 0.1 M PBS, pH 7.4, for 10 min. The sections were treated with 10  $\mu$ g/ml proteinase K (Boehringer Mannheim, Indianapolis, IN) in 0.1 M PBS for 20 min at 37°C, rinsed in 0.1 M PBS, then incubated in 0.2 M HCl for 10 min at room temperature (RT). After rinsing with 0.1 M PBS, the sections were acetylated with 0.25% (v/v) acetic anhydride in 0.1 M triethanolamine for 10 min at RT. Next, the sections were treated with RNase A (Sigma) (50  $\mu$ g/ml) at 37°C for 30 min, rinsed in 0.1 M PBS, and then dehydrated through a graded ethanol series up to 100% and allowed to air dry. Hybridization solution [50% (v/v) formamide, 2 $\times$  SSC, 10% w/v dextran




**Figure 2.** Both mtDNA $\Delta$ 5kb (chimeric probe) (*A*, *B*) or wild-type mtDNA (wild type 1) (*C*, *D*) only show an increase in vulnerable neurons in AD. In the hippocampus, we found that, whereas pyramidal neurons (*py*) show mtDNA increase in AD (*A*, *C*) compared with controls (*B*, *D*), other neuronal populations, e.g., granule cells of the dentate gyrus (*gr*), as well as glia, show no detectable signals. Scale bar, 100  $\mu$ m.



**Figure 3.** Cytochrome oxidase 1 immunoreactivity is increased several-fold in neurons in AD (*A*) compared with controls (*B*) and as shown by quantitative densitometric analysis (*C*) ( $p = 0.013$ ; Student's *t* test)  $\pm$  SEM. Scale bar, 50  $\mu$ m.


sulfate, 0.1 mg/ml sonicated salmon testis DNA (Sigma), 0.2 mg/ml yeast tRNA (Sigma), and 0.4–0.6  $\mu$ g/ml digoxigenin-labeled probe] was boiled for 10 min at 100°C. The sections were overlaid with 100  $\mu$ l of the hybridization solution, placed on a heating block for 5 min at 95°C, and then hybridized overnight at 40°C. After hybridization, the specimens were washed sequentially, once with 10 mM Tris-HCl, pH 7.4, 500 mM NaCl, 1 mM EDTA, twice with 2 $\times$  SSC (1 $\times$  SSC: 0.15 M NaCl, 15 mM sodium citrate, pH 7.4), and once with 0.1 $\times$  SSC. All washes were for 10 min at 37°C. The sections were then washed twice with Tris-buffered saline (TBS; 50 mM Tris-HCl, pH 7.6, 150 mM NaCl) for 10 min at RT. After incubation in 10% normal goat serum (NGS) for 1 hr at RT, slides were incubated with a monoclonal antibody to digoxigenin (1:250; Boehringer Mannheim) in 1% NGS overnight at 4°C and immunostained by the



**Figure 4.** Ultrastructural examination of a pyramidal neuron in the hippocampus after *in situ* hybridization by using probes to wild mtDNA (wild type 1) in AD (*A, B*) or mtDNA $\Delta$ 5kb (chimeric probe) (insets, *A, B*). The high density of gold particles was seen inside the vacuolar portions of lipofuscin granules, which likely represents autophagocytosis of damaged mitochondria in AD (*A*) and to a lesser extent in controls (*C*, inset). In contrast, mitochondria with cristae in both AD (*B*) and control cases (*C*) showed a lower level of mtDNA labeling (*C*). Scale bars: 1  $\mu$ m; 0.25  $\mu$ m (insets).

peroxidase–anti-peroxidase method (Sternberger, 1986), with 3,3' diaminobenzidine as cosubstrate. As controls, some specimens were processed as above but without the oligonucleotide probes and, in other cases, the hydrated sections were treated with a combination of 50 U/ml S1 nuclease (Boehringer Mannheim) and 50 U/ml DNase I (Boehringer Mannheim) overnight at 37°C. In both cases, no positive signal was detected. Optical densities of *in situ* hybridization were measured for manually outlined neuronal cell bodies with a Quantimet 570C Image Processing and Analysis Systems (Leica, Nussloch, Germany) as previously described (Nunomura et al., 1999).

**Electron microscopy.** Vibratome sections were treated and hybridized to probes as described above. Next, they were washed twice with TBS (50 mM Tris-HCl, pH 7.6, 150 mM NaCl) for 10 min at RT, incubated in 10% NGS for 2 hr at RT, and then incubated with a monoclonal antibody to digoxigenin (Boehringer Mannheim) diluted in 1% NGS overnight at



**Figure 5.** Examination of the morphology of mitochondria and lipofuscin in specimens removed at biopsy showed intact mitochondria (*A*), mitochondria with broken cristae (*B*), and vacuoles associated with lipofuscin indicated by a *V* and lipofuscin indicated by an *L* (*C*). Scale bars, 1  $\mu$ m.

4°C. After rinses in 10% NGS, gold (17 nm)-conjugated antibody to mouse IgG were applied for 4–24 hr and thoroughly rinsed in PBS. Finally the sections are post-fixed in 2.5% glutaraldehyde for 1 hr and again rinsed with PBS.

As controls, some specimens were processed as above but without the oligonucleotide probes, and in other cases the hydrated sections were treated with a combination of 50 U/ml S1 nuclease (Boehringer Mannheim) and 50 U/ml DNase I (Boehringer Mannheim) or with omission of the antibody to digoxigenin at 37°C for 1 hr. Finally, all sections were exposed to osmium tetroxide for 1 hr at RT, rinsed, dehydrated through acetone, and flat-embedded in Spurr's embedding media. Ultrathin sections were stained with uranylacetate and lead citrate and viewed in a JEOL 100CX electron microscope at 80 kV.

#### Immunocytochemistry

To identify the pathology of AD, we used antisera to  $\tau$  (Perry et al., 1991) to show NFT and a monoclonal antibody (4G8) to  $A\beta$  (Kim et al., 1988) for senile plaques. Nucleic acid and protein oxidative damage was respectively identified with antibodies to 8-hydroxyguanosine (8-OHG; Trevigen) and nitrotyrosine (clone 7A2; gift from J. S. Beckman, University of Alabama, Birmingham, AL). A monoclonal antibody to cytochrome oxidase-1 (clone 1D6; Molecular Probes, Eugene, OR) was also used in these studies. All immunostaining for light microscopy was by the peroxidase–anti-peroxidase method (Sternberger, 1986) and for electron microscopy by immunogold (Perry et al., 1985). Additionally, Congo red was used to identify the lesions of AD in some sections.

#### Morphometry

Micrographs were taken of neurons identified in the biopsy tissue at the plane containing the nucleolus at magnification of 5000 $\times$  and additionally at 20,000 $\times$  so that a montage including the entire cytoplasm could be made. Between 2 and 10 neurons were examined for each case. Photomicrographs were examined with a Zeiss stereomicroscope at 10–20 $\times$  and the following organelles were identified and counted for each neuron: intact mitochondria, mitochondria with broken cristae, vacuoles associated with lipofuscin, and lipofuscin. Total mitochondria was the sum of intact mitochondria and mitochondria with broken cristae. Each structure was outlined and the area was determined (NIH Image J program) and compared to the total cytoplasmic area excluding the nucleus.


Differences between groups were compared by the Student's *t* test as well as two-way ANOVA (*F* test).

## RESULTS

*In situ* analysis for mtDNA using oligonucleotide probes revealed a consistent and significant increase in mtDNA levels in cases of AD (Fig. 1*A,C,E*) compared with age-matched (Fig. 1*B,D,E*) or young controls (Fig. 1*E*) for all the probes used ( $p = 0.0034$ ;


Student's *t* test) with no significant difference between probes. Increases in both mtDNA $\Delta$  5kb (Fig. 2*A,B*) or wild-type mtDNA (Fig. 2*C,D*) was restricted to neurons, particularly those large vulnerable neurons of the hippocampus and neocortex. Neuronal labeling was seen in granular structures in the perinuclear cytoplasm and not noted in axons or dendrites. The sites labeled in the cytoplasm were DNase- but not RNase-sensitive (data not shown), whereas hybridization to nuclear sequences (*AluI* and 2) were restricted to the nucleus (data not shown). Importantly, in the hippocampus, we found that although pyramidal neurons (py) show mtDNA increase in AD (Fig. 2*A,C*) compared with controls (Fig. 2*B,D*), other neuronal populations, e.g., granule cells of the dentate gyrus (gr) as well as glia, show no increase. Importantly, a similar neuronal specificity was demonstrated in the frontal and temporal cortex, whereas in the cerebellum, a region only mildly affected by AD, there was no disease-related increase in mtDNA, wild-type or deleted, in any cellular populations (data not shown). The restriction of increased mtDNA to vulnerable neurons means that although the increase is striking in vulnerable neurons (Fig. 1), when examined in a regional context (Fig. 2), the change is small explaining the inability of previous biochemical analysis of tissue representing a variety of cell types to detect the substantial increase in mtDNA shown here. In our own comparison of mtDNA in AD and control cases by PCR, we did not find a significant and consistent increase in mtDNA (K. Hirai, M. A. Smith, and G. Perry, unpublished observations). No statistically significant correlation was found between our findings and post-mortem interval or agonal status by regression analysis.

The increase in mitochondrial components was not restricted to mtDNA because the mitochondrial protein cytochrome oxidase was also significantly elevated in the same neurons (Fig. 3) ( $p = 0.013$ ; Student's *t* test). To examine whether the increased mtDNA and mitochondrial protein noted in AD marked increased mitochondria or more mtDNA and cytochrome oxidase 1 per mitochondria, we examined the site of the increase by ultrastructure. We found only a weak *in situ* hybridization or immunoreactivity signal from mitochondria in AD (Fig. 4*C*) as well as control samples, not unexpected based on the expectation of 2–10 mtDNA for each individual mitochondria. However, we also



**Figure 6.** Morphometric analysis of the number (*A*), size (*B*), and percentage coverage (*C*) of cytoplasmic area by intact mitochondria, mitochondria with broken cristae, total mitochondria (intact plus mitochondria with broken cristae), vacuoles associated with lipofuscin, and lipofuscin in cases of AD and controls. Whereas percentage coverage of intact mitochondria decreases in AD ( $p = 0.012$ ), no significant changes were noted in vacuoles associated with lipofuscin ( $p = 0.056$ ), mitochondria with broken cristae ( $p > 0.10$ ), or lipofuscin ( $p > 0.08$ ). Although the size of lipofuscin did not change in AD ( $p = 0.095$ ), that of the vacuoles associated with lipofuscin significantly increased ( $p = 0.029$ ). Statistical comparison by the *F* test. \* indicates significant difference between AD and control cases.

found mtDNA and cytochrome oxidase-1 (data not shown) in the cytosol and in the case of mtDNA, also in vacuoles associated with lipofuscin (Fig. 4*A,B*). Confirming the light microscopic analysis, no mitochondria in axons or dendrites showed marked mtDNA proliferation (data not shown), and no signal was detected after the omission of either oligonucleotide probe, antibody to digoxigenin, or with previous treatment with DNases (data not shown). These findings indicate that the increase in



**Figure 7.** The distribution of neurons showing increased mtDNA $\Delta$ 5kb (chimeric probe) (*A*), 8-OHG (*B*), and nitrotyrosine (*C*) immunoreactivity in AD completely overlaps. Number indicates the same neurons in adjacent serial sections. Scale bar, 50  $\mu\text{m}$ .

mitochondrial markers in AD is related to their accumulation in the cytoplasm and the late autophagosomes of lipofuscin.

To evaluate the change in mitochondria in AD independent of DNA or protein-related probes as well as whether these changes could be noted in living patients before agonal state and soon after the onset of dementia, we quantitatively examined mitochondria and lipofuscin in specimens removed at biopsy (Fig. 5). Morphometric analysis (Fig. 6) showed that the area of intact mitochondria is significantly decreased in AD ( $p = 0.012$ ; *F* test) whereas there is no difference between the area of damaged mitochondria in AD or control cases. Because mitochondria are highly susceptible to morphological artifacts such as broken cristae, through inadequate fixation, that controls and AD cases showed similar frequency of mitochondria with broken cristae

suggests that fixation was similar for each group. Whereas the percentage of area for vacuoles associated with lipofuscin and lipofuscin were both increased in AD, the difference was not significant. As reported earlier (Dowson et al., 1998), we noted that the size of lipofuscin granules and vacuoles is larger in AD, but only the latter reached significance ( $p = 0.029$ ;  $F$  test). Although only six of the neurons in the AD cases contained neurofibrillary tangles, we found no significant differences in mitochondria or lipofuscin in those neurons compared with others.

Oxidative damage marked by 8-OHG and nitrotyrosine was increased in the same neurons displaying mtDNA proliferation (Fig. 7). Also, as we previously noted for 8-OHG (Nunomura et al., 1999) and nitrotyrosine (Smith et al., 1997), one of the most striking features of the mitochondrial abnormalities is its relatively uniform effect on entire populations of vulnerable neurons. Therefore, these data support an intimate topographic and probably temporal relationship between neuronal oxidative damage and mitochondrial abnormalities.

## DISCUSSION

In this study, we addressed whether there are mitochondrial abnormalities in vulnerable neurons by examining mtDNA, mitochondrial protein, and mitochondrial number in AD. We found both increased mtDNA and protein in AD. Ultrastructural examination showed the increased mtDNA and protein was found in the cytoplasm and in the vacuoles associated with lipofuscin, a lysosome that, in previous studies of cells, has been suggested as the site of mitochondrial degradation by autophagy (Brunk et al., 1992). Morphometry of the organelles of samples obtained at biopsy demonstrates there is, in fact, a significant decrease in mitochondria of vulnerable neurons in AD. These findings indicate vulnerable neurons in AD have increased mitochondrial degradation products, suggesting either greater turnover of mitochondria by autophagy or a reduction of proteolytic turnover leading to accumulation of mtDNA and mitochondrial protein. These mitochondrial components are likely damaged, because hydroxynonenal adducts to lipoic acid (Humphries and Szweda, 1998), the prosthetic group of two key Krebs cycle enzymes, can be found in the same vacuoles substantiates the view that these components are nonfunctional (G. Perry, M. A. Smith, and L. Szweda, unpublished observations). Also, because cytochrome oxidase must be membrane-bound to function, our findings are consistent with the low functional activity of many mitochondrial enzymes in AD (Wong-Riley et al., 1997).

The restriction of damaged mtDNA to neurons vulnerable to death in AD means that although the increase is striking on a per cell basis, when seen in the context of brain tissue, the change is very selective. The selectivity likely explains the conflicting results of previous biochemical analyses of mtDNA by PCR analysis. When we analyzed mtDNA changes by PCR, we also found only small differences between samples from AD and controls even in cases shown by *in situ* hybridization to show a fourfold increase (data not presented). This restriction to vulnerable neurons is the same found for oxidative damage, suggesting that an intimate relationship exists between them. The absence of mtDNA accumulation in non-neuronal cells does not mean that they do not also show changes in mitochondria. In a previous morphometric study, significant reduction in mitochondria density was found in endothelial cells (Stewart et al., 1992). Blass et al. (1990) and Blass and Gibson (1991) have also elegantly shown mitochondrial abnormalities in fibroblasts and other cells ob-

tained from patients with AD. The striking changes noted here may reflect as much how different categories of neurons deal with mitochondrial abnormalities, and such an interpretation is consistent with the findings of recent work with cytoplasmic hybrids that show mitochondria derived from non-neuronal cells from cases of AD have substantial energetic deficiencies (Ghosh et al., 1999; Khan et al., 2000; Trimmer et al., 2000). It is tempting to consider that the range of oxidative balance abnormalities noted in AD stem from a fundamental mitochondrial deficiency, but clearly more work is necessary to establish such a relationship. Although differences in mtDNA heredity may be important to our observations, the restriction of changes to vulnerable neurons only in cases of AD, rather than a more generalized change involving all cell types, indicates mitochondrial inheritance alone is not the only factor, but probably differences in mitochondrial turnover and metabolism as well as oxidant defense between different categories of cells are involved and require further clarification in future studies (Ito et al., 1999). Among the possible mechanisms underlying cellular specificity, reactive oxygen in vulnerable neurons may damage mitochondria while reducing their degradation (Friguet et al., 1994). Alternatively, mitochondria are likely not being transported to the axon properly consistent with the reduced number of microtubules seen in neurons in AD (A. D. Cash, M. A. Smith and G. Perry, unpublished observations).

That abnormalities occur in neurons lacking neurofibrillary tangles places mitochondria abnormalities as the earliest cytopathological change in AD. Other changes of AD could very well be linked to mitochondria because blockage of mitochondrial energy production shifts amyloid  $\beta$ -protein precursor metabolism to the production of more amyloidogenic forms of amyloid- $\beta$  (Gabuzda et al., 1994), induces the production of A68 antigen (Blass et al., 1990), and activates the mitogen-activated protein kinase pathway (Luo et al., 1997; Perry et al., 1999; Zhu et al., 2000, 2001), all features of AD.

## REFERENCES

- Blass JP, Gibson GE (1991) The role of oxidative abnormalities in the pathophysiology of Alzheimer's disease. *Rev Neurol (Paris)* 147:513–525.
- Blass JP, Baker AC, Ko L, Black RS (1990) Induction of Alzheimer antigens by an uncoupler of oxidative phosphorylation. *Arch Neurol* 47:864–869.
- Brunk UT, Jones CB, Sohal RS (1992) A novel hypothesis of lipofuscinogenesis and cellular aging based on interactions between oxidative stress and autophagocytosis. *Mutat Res* 275:395–403.
- Dowson JH, Mountjoy CQ, Cairns MR, Wilton-Cox H, Bondareff W (1998) Lipopigment changes in Purkinje cells in Alzheimer's disease. *J Alzheimer's Dis* 1:71–79.
- Friguet B, Stadtman ER, Szweda LI (1994) Modification of glucose-6-phosphate dehydrogenase by 4-hydroxy-2-nonenal. Formation of cross-linked protein that inhibits the multicatalytic protease. *J Biol Chem* 269:21639–21643.
- Gabuzda D, Busciglio J, Chen L, Matsudaira P, Yankner BA (1994) Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. *J Biol Chem* 269:13623–13628.
- Ghosh SS, Swerdlow RH, Miller SW, Sheeman B, Parker WD Jr, Davis RE (1999) Use of cytoplasmic hybrid cell lines for elucidating the role of mitochondrial dysfunction in Alzheimer's disease and Parkinson's disease. *Ann NY Acad Sci* 893:176–191.
- Humphries KM, Szweda LI (1998) Selective inactivation of alpha-ketoglutarate dehydrogenase and pyruvate dehydrogenase: reaction of lipoic acid with 4-hydroxy-2-nonenal. *Biochemistry* 37:15835–15841.
- Ito S, Ohta S, Nishimaki K, Kagawa Y, Soma R, Kuno S-Y, Komatsuzaki Y, Mizusawa H, Hayashi J-I (1999) Functional integrity of mitochondrial genomes in human platelets and autopsied brain tissues from elderly patients with Alzheimer's disease. *Proc Natl Acad Sci USA* 96:2099–2103.
- Katzman R (1986) Alzheimer's disease. *N Engl J Med* 314:964–973.

- Khachaturian ZS (1985) Diagnosis of Alzheimer's disease. *Arch Neurol* 42:1097–1105.
- Khan SM, Cassarino DS, Abramova NN, Keeney PM, Borland MK, Trimmer PA, Krebs CT, Bennett JC, Parks JK, Swerdlow RH, Parker Jr WD, Bennett Jr JP (2000) Alzheimer's disease cybrids replicate beta-amyloid abnormalities through cell death pathways. *Ann Neurol* 48:148–155.
- Kim KS, Miller DL, Sapienza VJ, Chen CMJ, Bai C, Grundke-Iqbal I, Currie JR, Wisniewski HM (1988) Production and characterization of monoclonal antibodies reactive to synthetic cerebrovascular amyloid peptide. *Neurosci Res Commun* 2:121–130.
- Luo Y, Bond JD, Ingram VM (1997) Compromised mitochondrial function leads to increased cytosolic calcium and to activation of MAP kinases. *Proc Natl Acad Sci USA* 94:9705–9710.
- McKhann GD, Drachman DA, Folstein MF, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer's disease. *Neurology* 34:939–944.
- Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. *Neurology* 41:479–486.
- Montine TJ, Amarnath V, Martin ME, Strittmatter WJ, Graham DG (1996) E-4-hydroxy-2-nonenal is cytotoxic and cross-links cytoskeletal proteins in P19 neuroglial cultures. *Am J Pathol* 148:89–93.
- Nakamura N, Hattori N, Tanaka M, Mizuno Y (1996) Specific detection of deleted mitochondrial DNA by in situ hybridization using a chimera probe. *Biochim Biophys Acta* 1308:215–221.
- Nunomura A, Perry G, Pappolla MA, Wade R, Hirai K, Chiba S, Smith MA (1999) RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. *J Neurosci* 19:1959–1964.
- Parker WD, Boyson SJ, Parks JK (1989) Abnormalities of the electron transport chain in idiopathic Parkinson's disease. *Ann Neurol* 26:719–723.
- Perry G, Rizzuto N, Autilio-Gambetti L, Gambetti P (1985) Paired helical filaments from Alzheimer disease patients contain cytoskeletal components. *Proc Natl Acad Sci USA* 82:3916–3920.
- Perry G, Kawai M, Tabaton M, Onorato M, Mulvihill P, Richey P, Morandi A, Connolly JA, Gambetti P (1991) Neuropil threads of Alzheimer's disease show a marked alteration of the normal cytoskeleton. *J Neurosci* 11:1748–1755.
- Perry G, Roder H, Nunomura A, Takeda A, Friedlich AL, Zhu X, Raina AK, Holbrook N, Siedlak SL, Harris PLR, Smith MA (1999) Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. *NeuroReport* 10:2411–2415.
- Praprotnik D, Smith MA, Richey PL, Vinters HV, Perry G (1996a) Plasma membrane fragility in dystrophic neurites in senile plaques of Alzheimer's disease: an index of oxidative stress. *Acta Neuropathol* 91:1–5.
- Praprotnik D, Smith MA, Richey PL, Vinters HV, Perry G (1996b) Filament heterogeneity within the dystrophic neurites of senile plaques suggests blockage of fast axonal transport in Alzheimer's disease. *Acta Neuropathol* 91:226–235.
- Sayre LM, Zelasko DA, Harris PLR, Perry G, Salomon RG, Smith MA (1997) 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. *J Neurochem* 68:2092–2097.
- Smith MA (1998) Alzheimer disease. In: *International review of neurobiology* (Bradley JY, Harris RA, eds), pp 1–54. San Diego: Academic.
- Smith MA, Perry G, Richey PL, Sayre LM, Anderson VM, Beal MF, Kowall N (1996) Oxidative damage in Alzheimer's. *Nature* 382:120–121.
- Smith MA, Harris PLR, Sayre LM, Beckman JS, Perry G (1997) Widespread peroxynitrite-mediated damage in Alzheimer's disease. *J Neurosci* 17:2653–2657.
- Sternberger LA (1986) *Immunocytochemistry*, Ed 3. New York: Wiley.
- Stewart PA, Hayakawa K, Akers M-A, Vinters HV (1992) A morphometric study of the blood-brain barrier in Alzheimer's disease. *Lab Invest* 67:734–742.
- Trimmer PA, Swerdlow RH, Parks JK, Keeney P, Bennett Jr JP, Miller SW, Davis RE, Parker Jr WD (2000) Abnormal mitochondrial morphology in sporadic Parkinson's and Alzheimer's disease cybrid cell lines. *Exp Neurol* 162:37–50.
- Wong-Riley M, Antuono P, Ho K-V, Egan R, Hevner R, Liebl W, Huang Z, Rachel R, Jones J (1997) Cytochrome oxidase in Alzheimer's disease: biochemical, histochemical, and immunohistochemical analyses of the visual and other systems. *Vision Res* 37:3593–3608.
- Zhu X, Rottkamp CA, Boux H, Takeda A, Perry G, Smith MA (2000) Activation of p38 pathway links tau phosphorylation, oxidative stress and cell cycle related events in Alzheimer disease. *J Neuropathol Exp Neurol* 59:880–888.
- Zhu X, Raina AK, Rottkamp CA, Aliev G, Perry G, Boux H, Smith MA (2001) Activation and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. *J Neurochem* 76:435–441.